Ali Raza, George Dikdan, Kunj K. Desai, Asif Shareef, Helen Fernandes, Virginie Aris, Andrew N. de la Torre, Dorian Wilson, Adrian Fisher, Patricia Soteropoulos, Baburao Koneru – 19 February 2010 – The benefits of ischemic preconditioning (IPC) in reducing ischemia/reperfusion injury (IRI) remain indistinct in human liver transplantation (LT). To further understand mechanistic aspects of IPC, we performed microarray analyses as a nested substudy in a randomized trial of 10‐minute IPC in 101 deceased donor LTs.

Ronald W. Busuttil – 12 February 2010

Woo Young Shin, Kyung‐Suk Suh, Hae Won Lee, Joohyun Kim, Taehoon Kim, Nam‐Joon Yi, Kuhn Uk Lee – 12 February 2010 – Liver transplantation is regarded as an effective treatment for early hepatocellular carcinoma (HCC). However, some patients experience recurrence and subsequently rapid progression of the disease. We investigated prognostic factors affecting survival after recurrence in patients who underwent adult living donor liver transplantation (LDLT) for HCC. From October 1992 to December 2005, 138 adult patients underwent LDLT for HCC.

Dinesh Jothimani, Timothy J. S. Cross – 8 February 2010

Jean F. Botha, Alan N. Langnas, B. Daniel Campos, Wendy J. Grant, Christopher E. Freise, Nancy L. Ascher, David F. Mercer, John P. Roberts – 8 February 2010 – Adult‐to‐adult living donor liver transplantation (AA‐LDLT) has better outcomes when a graft weight to recipient weight ratio (GW/RW) > 0.8 is selected. A smaller GW/RW may result in small‐for‐size syndrome (SFSS). Portal inflow modulation seems to effectively prevent SFSS. Donor right hepatectomy is associated with greater morbidity and mortality than left hepatectomy.

Shin Hwang, Sung‐Gyu Lee, Chul‐Soo Ahn, Deok‐Bog Moon, Ki‐Hun Kim, Kyu‐Bo Sung, Gi‐Young Ko, Tae‐Yong Ha, Gi‐Won Song, Dong‐Hwan Jung, Dong‐Il Gwon, Kyoung‐Won Kim, Nam‐Kyu Choi, Kwan‐Woo Kim, Young‐Dong Yu, Gil‐Chun Park – 8 February 2010 – The incidence of clinically significant right hepatic vein (RHV) stenosis after adult living donor liver transplantation has been higher than expected. In this study, an assessment of the risk factors for the development of RHV stenosis in this context was undertaken.

Massimo De Giorgio, Stefano Vezzoli, Eric Cohen, Elia Armellini, Maria Grazia Lucà, Giulianna Verga, Domenico Pinelli, Roberto Nani, Maria Grazia Valsecchi, Laura Antolini, Michele Colledan, Stefano Fagiuoli, Mario Strazzabosco – 8 February 2010 – Transplantation is the treatment of choice for hepatocellular carcinoma (HCC) meeting the Milan criteria. HCC and chronic liver diseases have distinct natural histories for which an equitable transplant policy must account.

John F. Renz – 8 February 2010

Franklin Greif, Ziv Ben‐Ari, Rasim Taya, Orit Pappo, Efrat Kurtzwald, Yelena Cheporko, Amiram Ravid, Edith Hochhauser – 8 February 2010 – The only currently offered curative option for many patients with primary or secondary liver tumors is the resection of hepatic tumors. The aim of this study was to evaluate the role of recombinant human erythropoietin (rhEPO) in liver protection and regeneration after subtotal hepatectomy in rats. Rats undergoing 70% hepatectomy received an intraperitoneal injection of saline (control) or rhEPO (4 U/g) 30 minutes prior to resection.

Fabio Piscaglia, Alice Gianstefani, Matteo Ravaioli, Rita Golfieri, Alberta Cappelli, Emanuela Giampalma, Elisabetta Sagrini, Grazia Imbriaco, Antonio Daniele Pinna, Luigi Bolondi – 8 February 2010 – Malignant portal vein thrombosis is a contraindication for liver transplantation. Patients with cirrhosis and early hepatocellular carcinoma (HCC) may have either malignant or benign (fibrin clot) portal vein thrombosis.